Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA. Abraham E, et al. Among authors: leighton a. Crit Care Med. 2001 Nov;29(11):2081-9. doi: 10.1097/00003246-200111000-00007. Crit Care Med. 2001. PMID: 11700399 Clinical Trial.
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P; Lenercept Study Group. Abraham E, et al. Among authors: leighton a. Crit Care Med. 2001 Mar;29(3):503-10. doi: 10.1097/00003246-200103000-00006. Crit Care Med. 2001. PMID: 11373411 Clinical Trial.
Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
Pittet D, Harbarth S, Suter PM, Reinhart K, Leighton A, Barker C, Macdonald F, Abraham E. Pittet D, et al. Among authors: leighton a. Am J Respir Crit Care Med. 1999 Sep;160(3):852-7. doi: 10.1164/ajrccm.160.3.9809033. Am J Respir Crit Care Med. 1999. PMID: 10471608 Clinical Trial.
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G. Traynor AM, et al. Among authors: leighton am. Cancer Chemother Pharmacol. 2011 Feb;67(2):305-14. doi: 10.1007/s00280-010-1318-9. Epub 2010 Apr 13. Cancer Chemother Pharmacol. 2011. PMID: 20386909 Free PMC article. Clinical Trial.
Losses and emissions in polypropylene recycling from household packaging waste.
Kasper JB, Parker LA, Postema S, Höppener EM, Leighton AH, Finnegan AMD, Rutten SB, Nijman J, Larasati A, Soares ACC, van Eijk MCP. Kasper JB, et al. Among authors: leighton ah. Waste Manag. 2025 Jan 1;191:230-241. doi: 10.1016/j.wasman.2024.11.029. Epub 2024 Nov 19. Waste Manag. 2025. PMID: 39566230 Free article.
Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip.
Conway J, Delanois RE, Mont MA, Stavrakis A, McPherson E, Stolarski E, Incavo S, Oakes D, Salvagno R, Adams JS, Kisch-Hancock A, Tenorio E, Leighton A, Ryser S, Kauvar LM, Bernthal NM. Conway J, et al. Among authors: leighton a. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0065524. doi: 10.1128/aac.00655-24. Epub 2024 Jul 16. Antimicrob Agents Chemother. 2024. PMID: 39012102 Free PMC article. Clinical Trial.
133 results